Department of Ophthalmology, Justus-Liebig-University Giessen, Friedrichstr. 18, 35390 Giessen, Germany.
Sensors (Basel). 2017 Jan 13;17(1):145. doi: 10.3390/s17010145.
In this paper we describe a two-component BRET (bioluminescence resonance energy transfer)-based method to detect vascular endothelial growth factor (VEGF) molecules in unknown samples as the basis for subsequent in vivo use. A luminescent VEGF binding molecule, which binds in the receptor binding motif of VEGF, is used as the energy donor, transferred to a fluorophore-coupled VEGF binding molecule (acceptor), which binds to the neuropilin binding motif of VEGF, thus enabling energy transfer from the donor to the acceptor molecule. This leads to the emission of light at a longer wavelength and thus the generation of an increased BRET signal only when VEGF is bound to both the donor and acceptor molecules. We further describe a novel BRET pair that uses the mutant luciferase RLuc8 and the chemically engineered fluorophore PerCP-Cy5.5, which exhibits superior peak separation of approximately 300 nm. The implantation of capsules consisting of the two BRET components in solution, permeable for VEGF for its in vivo detection, would provide a new and improved method for monitoring VEGF-induced pathologies and thus an adjustment of therapy to patient needs.
本文描述了一种基于双组分 BRET(生物发光共振能量转移)的方法,用于检测未知样品中的血管内皮生长因子 (VEGF) 分子,作为后续体内应用的基础。一个发光的 VEGF 结合分子,它结合在 VEGF 的受体结合基序中,作为能量供体,转移到与 VEGF 的神经纤毛结合基序结合的荧光素偶联的 VEGF 结合分子(受体)上,从而使能量从供体转移到受体分子。这导致更长波长的光发射,从而仅在 VEGF 与供体和受体分子结合时才产生增加的 BRET 信号。我们进一步描述了一种新的 BRET 对,它使用突变的荧光素酶 RLuc8 和化学工程化的荧光染料 PerCP-Cy5.5,其峰分离约为 300nm。将包含两种 BRET 成分的溶液胶囊植入体内,可检测 VEGF,这将提供一种新的、改进的方法来监测 VEGF 诱导的病变,并根据患者的需要调整治疗。